Abstract:Progressive kidney fibrosis precedes end-stage renal failure in up to a third of patients with diabetes mellitus. Elevated intra-renal transforming growth factor-β (TGF-β) is thought to underlie disease progression by promoting deposition of extracellular matrix and epithelialmesenchymal transition. GW788388 is a new TGF-β type I receptor inhibitor with a much improved pharmacokinetic profile compared with SB431542. We studied its effect in vitro and found that it inhibited both the TGF-β type I and type II receptor kinase activities, but not that of the related bone morphogenic protein type II receptor. Further, it blocked TGF-β-induced Smad activation and target gene expression, while decreasing epithelialmesenchymal transitions and fibrogenesis. Using db/db mice, which develop diabetic nephropathy, we found that GW788388 given orally for 5 weeks significantly reduced renal fibrosis and decreased the mRNA levels of key mediators of extracellular matrix deposition in kidneys. Our study shows that GW788388 is a potent and selective inhibitor of TGF-β signalling in vitro and renal fibrosis in vivo. Abbreviations ActRII, activin type II Receptor; ALK, activin receptor-like kinase; caALK, constitutively active ALK; β-gal, β-galactosidase; BMP, bone morphogenic protein; BMPRII, BMP type II receptor; BRE, BMP responsive element; COL, collagen; CTGF, connective tissue growth factor; ECM, extracellular matrix; EMT, epithelial to mesenchymal transition; FN, fibronectin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GW788388, 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl) pyridin-2-yl)-N-(tetrahydro-2Hpyran4-yl) benzamide; MMP, matrix metalloproteinase; NMuMG, namru murine mammary gland; PAI-1, plasminogen activator inhibitor 1; PAS, picric acid stain; PSmad, phosphorylated Smad; RCC4, renal cell carcinoma; RT-PCR, reverse transcriptase polymerase chain reaction; SB431542, 4-(5-benzo(1,3) dioxol5-yl-4-pyridin-2-yl-1H -imidazol-2-yl)-benzamide; Smad, small phenotype and mothers against DPP related protein; α-SMA, α-smooth muscle actin; TGF-β, transforming growth factor-β; TβRII, TGF-β type II receptor; TIMP, Tissue inhibitor of metalloproteinase; VHL, von Hippel Lindau.

Inhibition of Wnt/β-catenin signaling reduces renal fibrosis in murine glycogen storage disease type Ia

Targeted Inhibition of Β-Catenin/cbp Signaling Ameliorates Renal Interstitial Fibrosis

Conditional ablation of glycogen synthase kinase 3 β in postnatal mouse kidney

Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b

The β isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy.

Mice Overexpressing Latent Tgf-Beta 1 Are Protected Against Renal Fibrosis In Obstructive Kidney Disease

SGLT1 Knockdown Attenuates Cardiac Fibroblast Activation in Diabetic Cardiac Fibrosis

Hepatorenal Correction in Murine Glycogen Storage Disease Type I with A Double-Stranded Adeno-Associated Virus Vector

Permissive Effect of GSK3β on Profibrogenic Plasticity of Renal Tubular Cells in Progressive Chronic Kidney Disease.

Inhibition of Glycogen Synthase Kinase 3β Alleviates Chronic Renal Allograft Dysfunction in Rats

Inhibition Of Glycogen Synthase Kinase-3 Beta Attenuates Acute Kidney Injury In Sodium Taurocholate-Induced Severe Acute Pancreatitis In Rats

Oral administration of GW788388, a kinase inhibitor of the TGF-β type I and type II receptors, reduces renal fibrosis in db/db mice

PKB/SGK-Resistant GSK-3 Signaling Following Unilateral Ureteral Obstruction

WNT1‐inducible‐signaling Pathway Protein 1 Regulates the Development of Kidney Fibrosis Through the TGF‐β1 Pathway

IGF-1/IGF-1R Blockade Ameliorates Diabetic Kidney Disease Through Normalizing Snail1 Expression in a Mouse Model

Molecular biology and gene therapy for glycogen storage disease type Ib

GSK3β Inhibition Reduced Vascular Calcification in Ins2Akita/+ Mice

[Impact of Glycogen Synthase Kinase-3Β (Gsk-3Β) Inhibitor on Wnt and NF-κB Signal Pathways in a Rat Model of Diabetic Nephropathy].

[Advances on the Management of Renal Lesion in Glycogen Storage Disease Type I].

Wnt Pathway Inhibition with the Porcupine Inhibitor LGK974 Decreases Trabecular Bone but not Fibrosis in a Murine Model with Fibrotic Bone

WNT1-Inducible Signaling Protein-1 Mediates Renal Fibrosis Via Autophagy Both in Vivo and in Vitro